Erschienen in:
01.04.2009 | Review
Clinical implications of molecular genetic aberrations in acute myeloid leukemia
verfasst von:
Sebastian Scholl, Hans-Joerg Fricke, Herbert G. Sayer, Klaus Höffken
Erschienen in:
Journal of Cancer Research and Clinical Oncology
|
Ausgabe 4/2009
Einloggen, um Zugang zu erhalten
Abstract
The role of different cytogenetic changes has been extensively evaluated in patients with acute myeloid leukemia (AML), and cytogenetic analysis of AML blasts is essential to form prognostic subgroups in order to stratify for the extent of therapy. Nevertheless, 40–45% of AML patients lack such cytogenetic markers, i.e., cytogenetically normal AML (CN-AML). In the past decade, different molecular aberrations were identified in AML and especially CN-AML can now be discriminated into certain prognostic subgroups. This review considers the latest advances to define the prognostic impact of molecular aberrations in AML and gives insights how such molecular markers can be applied for analysis of minimal residual disease. Furthermore, therapeutic implications as well as the potential role of new methodological techniques in analyzing expression patterns of AML blasts are discussed.